A Review on Latent Autoimmune Diabetes in Adults.

Autor:	Ravikumar V; Medical Education, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education & Research, Wardha, IND., Ahmed A; Medical Education, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education & Research, Wardha, IND., Anjankar A; Biochemistry, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education & Research, Wardha, IND.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Oct 29; Vol. 15 (10), pp. e47915. Date of Electronic Publication: 2023 Oct 29 (Print Publication: 2023).
DOI:	10.7759/cureus.47915
Abstrakt:	Latent autoimmune diabetes (LADA) is an unique form of diabetes that has characteristics of both type 1 and type 2 diabetes. Type 1.5 diabetes also known as LADA is occasionally confused for type 2 diabetes because there is delay in presenting features and early insulin independence. LADA, on the other hand, is an autoimmune disorder that differs from type 2 diabetes in that autoantibodies against pancreatic beta cells are what characterise it. Insulin production eventually diminishes due to the autoimmune destruction of pancreatic beta cells as a result of the pathophysiology of LADA. Autoantibodies to glutamic acid decarboxylase (GAD), islet antigen-2 (IA-2), and insulin are frequently detected in LADA patients. These autoantibodies have important implications for therapy strategies and are essential in differentiating LADA from type 2 diabetes. LADA clinical management is very challenging. The aim of this article is to view the characteristics, disease presentation, diagnostic challenges, progression and treatment modalities of LADA. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Ravikumar et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu